Notable Analyst Calls: Esperion Therapeutics (ESPR), Zebra Technologies (ZBRA), Tesaro, Inc. (TSRO), Nike (NKE)

Analysts at Credit Suisse downgraded Esperion Therapeutics, Inc. (ESPR) from ‘Neutral’ to ‘Underperform’ in a research report issued to clients on Wednesday.

Esperion Therapeutics Inc., currently with a median Street price target of $43.00 and a high target of $80.00, dropped $6.39 to $9.79 in recent trading. Shares of the $220.90 million market cap company are down 79.33% year-over-year and 27.31% year-to-date.
—
Zebra Technologies Corporation (ZBRA) was downgraded from ‘Buy’ to ‘Neutral’ at Northcoast.

Shares have traded today between $48.84 and $52.31 with the price of the stock fluctuating between $48.51 to $117.00 over the last 52 weeks.

Shares of Zebra have lost $1.28 to $49.48 in mid-day trading on Wednesday, giving it a market cap of roughly $2.6 billion. The stock traded as high as $117.00 on July 20, 2015.
—
Tesaro, Inc. (TSRO) was reiterated an ‘Outperform’ by FBR Capital analysts on Wednesday. The broker also raised its price target on the stock to $93 from $65 following the company’s positive late-stage trial results. Tesaro announced that its Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival. FBR Capital analysts said they are very impressed by the results and believe niraparib could now address a larger market than its competitors. They expects Tesaro to submit NDA and MAA filings for niraparib in the fourth-quarter of 2016.

Tesaro surged 115% intraday to a new all time high of $80.69 following its positive Phase III ovarian cancer data.
—
Nike, Inc. (NKE) was reiterated as ‘Buy’ at Jefferies. The firm however, cut its price target on the name to $65 from $67 after the company reported a mixed quarter and disappointing investors with its future orders guidance.

In its 4Q16 report, the athletic-apparel giant said it earned $0.49 per share, one penny above the $0.48 per share analysts were expecting. Revenue rose 6.0% year-over-year to $8.24 billion, missing forecasts for $8.28 billion. Worldwide futures orders rose by 11%, below forecasts for 13%. That’s excluding the impact of currency changes.

Jefferies said they “remain upbeat” about Nike stock in the long term, they noted however, they expect market share oscillation to pressure NKE in the first half of FY 2017.

Shares of Nike gained 2.92% to $54.64 Wednesday afternoon.